1. Isotope-Labeled Compounds

Isotope-Labeled Compounds

Isotope-labeled compounds are chemical substances in which some atoms in their molecules are replaced by isotope atoms. The range of stable isotope products can cover from gases to complex molecules. Isotope-labeled compounds could provide a site-specific investigation of structures, making molecules easily detectable by mass spectrometry and NMR, and maintaining the physico-chemical properties of the target molecule at the same time.

MCE isotope-labeled compounds are all stable isotope-labeled compounds and are non-radioactive labeled substances. MCE isotope-labeled compounds are unique tools for identifying and understanding biological and chemical processes. Stable isotope-labeled products are now getting more and more popular among scientists. The scope of application is gradually penetrating into various scientific fields, such as life sciences, food and medicine, agriculture, environment, geology, etc. Stable isotope-labeled compounds have a wide range of applications in the Life Science areas, such as Metabolomics, Proteomics, Clinical studies, Deuterium drugs, etc.

Isotope-Labeled Compounds (2626):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15162A
    D8-MMAE 2070009-72-0 99.29%
    D8-MMAE (D8-Monomethyl auristatin E) is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
    D8-MMAE
  • HY-19939S
    VX-984 1476074-39-1 99.36%
    VX-984 is a potent DNA-PK inhibitor.
    VX-984
  • HY-131968
    BMS-986202 1771691-34-9 99.46%
    BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 of 0.19 nM and a Ki of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research.
    BMS-986202
  • HY-15579AS
    D8-MMAF hydrochloride 98.97%
    D8-MMAF hydrochloride is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.
    D8-MMAF hydrochloride
  • HY-A0020S
    Eldecalcitol-d6 99.26%
    Eldecalcitol-d6 is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.
    Eldecalcitol-d6
  • HY-13631AS
    Exatecan D5 mesylate
    Exatecan D5 mesylate (DX8951f-D5) is deuterium labeled Exatecan Mesylate. Exatecan mesylate is a DNA topoisomerase I inhibitor, with an IC50 of 0.975 μg/mL.
    Exatecan D5 mesylate
  • HY-104077S
    Remdesivir-D5 99.58%
    Remdesivir-D5 (GS-5734-D5) is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.
    Remdesivir-D5
  • HY-B0113S
    Omeprazole D3 922731-01-9 ≥98.0%
    Omeprazole D3 (H 16868 D3) is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.
    Omeprazole D3
  • HY-50767S
    Palbociclib D8 1628752-83-9 99.84%
    Palbociclib D8 (PD 0332991 D8) is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.
    Palbociclib D8
  • HY-W050026S
    Phenylacetylglutamine-D5 1331909-01-3 98.01%
    Phenylacetylglutamine-D5 (NSC 203800-D5;Phenylacetyl-L-glutamine-D5) is a deuterated form of Phenylacetylglutamine. Phenylacetylglutamine is a colonic microbial metabolite from amino acid fermentation.
    Phenylacetylglutamine-D5
  • HY-15772S
    Osimertinib D6 1638281-44-3 99.70%
    Osimertinib D6 (AZD-9291 D6) is a deuterium labeled Osimertinib. Osimertinib is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
    Osimertinib D6
  • HY-B0421S
    Mycophenolic acid D3 1185242-90-3 ≥98.0%
    Mycophenolic acid D3 (Mycophenolate D3) is deuterium labeled Mycophenolic acid, which is an an immunosuppresant drug and has potent anti-proliferative activity.
    Mycophenolic acid D3
  • HY-76814
    Calcitriol D6 78782-99-7 99.12%
    Calcitriol D6 is the deuterated form of Calcitriol(1,25-Dihydroxyvitamin D3; Rocaltrol ), which is the hormonally active form of vitamin D, Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).
    Calcitriol D6
  • HY-113468AS
    3-O-Methyldopa D3 586954-09-8 ≥99.0%
    3-O-Methyldopa D3 (3-Methoxy-L-tyrosine D3) is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine.
    3-O-Methyldopa D3
  • HY-B0801S
    Fexofenadine D6 548783-71-7 ≥98.0%
    Fexofenadine D6 (MDL-16455 D6) is deuterium labeled is Fexofenadine, which is an antihistamine pharmaceutical agent.
    Fexofenadine D6
  • HY-10201S
    Sorafenib-d3 1130115-44-4 99.57%
    Sorafenib-d3 (Bay 43-9006-d3) is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.
    Sorafenib-d3
  • HY-15331
    VD3-D6 118584-54-6 ≥98.0%
    VD3-D6(Vitamin D3-26,26,26,27,27,27-d6) is the deuterated form of Vitamin D3; tools for determination of Vitamin D3 metabolites in human serum.
    VD3-D6
  • HY-B0590S
    Tetrabenazine D6 1392826-25-3 ≥99.0%
    Tetrabenazine D6 is the deuterium labeled Tetrabenazine, which is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.
    Tetrabenazine D6
  • HY-126242S
    Tyk2-IN-7 1609391-90-3 99.66%
    Tyk2-IN-7 (Compound 48) is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 (Compound 48) provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 (Compound 48) provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model.
    Tyk2-IN-7
  • HY-110228
    Metformin D6 hydrochloride 1185166-01-1 ≥98.0%
    Metformin D6 hydrochloride is a deuterium labeled Metformin hydrochloride. Metformin hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to activation of AMPK, enhancing insulin sensitivity for type 2 diabetes research. Metformin hydrochloride triggers autophagy.
    Metformin D6 hydrochloride